PFE Jan 2025 50.000 call
| Previous close | 0.1500 |
| Open | 0.2500 |
| Bid | 0.1400 |
| Ask | 0.1600 |
| Strike | 50.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.1500 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 15.09k |
Motley FoolPfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not be advancing into late-stage clinical trials. Now, the company's bid to capture portions of the extremely lucrative type 2 diabetes and obesity drug markets looks like it's in trouble.
Insider Monkey10 Cheap Dividend Stocks with High Yields
In this article, we discuss 10 cheap dividend stocks with high yields. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Cheap Dividend Stocks with High Yields. In 2022, value stocks did better than growth stocks, marking the first time of value outperformance […]
ZacksPharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
